Masakazu Toi

46PUBLICATIONS
212CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Biomedical imagingTraditional Chinese medicine and treatments
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (46)

|Sep 26, 2026
Accelerated Pancreatic Volume Loss as a Potential Pre-Diagnostic Imaging Biomarker for Pancreatic Cancer Risk Enrichment: An AI-Assisted Volumetric Study.

|May 19, 2026
Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial.

|Apr 16, 2026
Dynamic changes in serum HER2-peptide-specific autoantibodies predict response to neoadjuvant therapy in HER2-positive breast cancer.

|Mar 19, 2026
Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study.

Norikazu Masuda, Hiroyuki Yasojima, Hiroko Bando

|Jan 27, 2026
Correction: Honda et al. Visual Evaluation of Ultrafast MRI in the Assessment of Residual Breast Cancer After Neoadjuvant Systemic Therapy: A Preliminary Study Association with Subtype. Tomography 2022, 8, 1522-1533.

Maya Honda, Masako Kataoka, Mami Iima

|Nov 12, 2025
Locoregional indicators of systemic spread in breast cancer: insights from standard-of-care imaging and ¹⁸F-FDG PET/CT.

Yurika Kitano, Kanae K Miyake, Tomomi W Nobashi

Pageof 8

Frequent Collaborators

11 joint publications

Norikazu Masuda

8 joint publications

Masako Kataoka

7 joint publications

Kanae Kawai Miyake

6 joint publications

Takayoshi Ishimori